Another Generic Liraglutide launch: Hikma Phamaceuticals
A new player enters the generic GLP1 market - Hikma Pharmaceuticals. As the second generic Liraglutide provider, accessibility of GLP1s has never been better.
2025 is shaping up to be a great year for GLP1 Receptor Agonists and it hasn't even started yet.
Check out our quick explainer
The FDA has reaffirmed it's commitment to enhancing accessibility of GLP1s with the announcement of a second approved generic for GLP1:
Office of the Commissioner
The lucky company this time is Hikma Pharmaceuticals:
Who are Hikma Pharmaceuticals?
Hikma is a now British pharmaceutical firm that was first started in 1978 in Jordan. Hikma isn't as old as Eli Lilly and Novo Nordisk's rivalry, but it's certainly not a newcomer to the pharmaceutical industry at all.
Contributors to Wikimedia projects
Similar to TEVA, Hikma specializes in creating generics – meaning that they are likely very much excited to increase the supply of Liraglutide available on the market.
Hikma produces many different kinds of injectables, even including Fentanyl (!):
- Argatroban (anti-coagulant)
- Fentanyl (opioid)
- Phenylephrine (Decongestant)
- Methocarbamol (Musco-skeletal pain medication)
Hikma's produces drugs that can be taken orally as well, which are mostly antibiotics:
What will a new generic mean for the GLP1 market?
Similar to TEVA, we expect Hikma pharmacy's entrance into the GLP1 market to boost accessibility of the drugs.
Whether it's HIMS's recent move to Liraglutide, various other companies that are worried about compounding bans, or the average consumer, more choices in manufacturing means lower prices and more competition.
GLP1.Guide Staff
While the wider GLP1 market is huge, Liraglutide is also a large player inside of that:
According to IQVIA, US sales of Liraglutide Injection, 6 mg/mL, were approximately $1.3 billion in the 12 months ending October 2024.
In just 12 months, $1.3B in approximate sales of a relatively old formulation of GLP1 is quite impressive.
Hikma is also a top 3 supplier of injectable drugs in the US – so their track record is proven.
Future patent expirations are likely to be picked up by the same companies
Now that there's a clear demand for patent-expired medication in the GLP1 space the market can likely expect these large companies to make the same moves after new drugs lose their patent protection.
Another move in 2025 is likely to be Aldyxin:
GLP1.Guide Staff
While Aldyxin itself may not be a supremely effective GLP1 RA, it can now be combined with other formulations and a whole new world of exploration, experimentation and research can begin.
